Pathology Company Healius Faces Financial Struggles

  • 📰 FinancialReview
  • ⏱ Reading Time:
  • 30 sec. here
  • 8 min. at publisher
  • 📊 Quality Score:
  • News: 36%
  • Publisher: 90%

Healthcare News

Pathology,Healius,Australia

Healius, a pathology company in Australia, is experiencing a decline in its sharemarket capitalisation and had to undergo an emergency capital raising. The chairwoman resigned before facing a potential vote for re-election.

A visit to the doctor regularly involves the GP needing a blood sample. The patient is sent to a collection centre where a kindly nurse extracts blood from a vein, packages up the test tubes for transportation to a pathology lab for examination, with results returned to the GP for a follow-up appointment. The ageing population and strong migration levels of up to 500,000 new arrivals annually mean pathology companies are seemingly in a sweet spot for demand for their services.

in Australia’s pathology sector, is battling a fall from grace which has stripped $2 billion from its sharemarket capitalisation in two years. It was forced by its banks into an emergency capital raising of $187 million at $1.20 a share on November 20. The heavily discounted rights issue triggered a rapid boardroom overhaul as chairwomanHealius CEO Maxine Jaquet at the annual meeting on November 28.Ms Macdonald, chairwoman since October 2022, jumped before she was pushed. Proxies showed she would have lost a vote for her re-election at the annual meeting on November 2

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 2. in BUSİNESS

Business Business Latest News, Business Business Headlines